Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated November 16, 2020, announces a General Meeting of Shareholders scheduled for December 8, 2020. The filing serves to provide the Notice and Proxy Statement regarding a proposed corporate restructuring of the company's share capital.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments rather than operational financial performance.
Material Changes and Proposals
- Currency Change: The Company proposes changing the currency of its ordinary shares from pounds sterling to US dollars to align with its accounting currency.
- Par Value Reduction: The nominal (par) value of an ordinary share will be reduced to USD 0.0001 to increase financial and capital flexibility.
- Deferred Shares: The reduction in nominal value will technically involve the issuance of deferred shares, which will be immediately cancelled.
- Shareholder Impact: The number of ordinary shares in issue and each shareholder's proportionate interest will remain unchanged. Voting, dividend, and capital rights will remain the same.
Management Commentary and Rationale
Management states that aligning the share currency with the accounting currency is expected to reduce accounting costs. Additionally, the change is anticipated to increase the Company's accounting net asset value by removing the requirement to account for stock warrants as liabilities. The reduction in par value is intended to provide a round number and enhance capital flexibility.
Investor Verification Checklist
- Verify the outcome of the shareholder vote at the December 8, 2020, General Meeting regarding the currency and par value changes.
- Confirm the effective date of the currency conversion from pounds sterling to US dollars.
- Review subsequent filings to assess the actual impact on accounting net asset value and the treatment of stock warrants.
- Ensure there are no unexpected tax implications for shareholders resulting from the currency and par value adjustments.